We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » AbbVie and J&J Win Federal Patent Case, Thwarting Generic of Blockbuster Imbruvica
AbbVie and J&J Win Federal Patent Case, Thwarting Generic of Blockbuster Imbruvica
A federal appeals court sided with AbbVie’s Pharmacyclics and Johnson & Johnson’s Janssen Biotech this week, affirming that a generic version of the blockbuster cancer drug Imbruvica (ibrutinib) infringes their patents.